Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

MD Anderson is

going to focus on the pan exon 20 trial

. When I walked away from my computer this morning after I posted that, I realized tha MDA trial included 1st-line patients in the EGFR cohort almost from the beginning. So much talk about JT saying we're going to test it in 1st-line that I almost forgot this fact. I'm not sure about MDA trial testing in 1st-line HER2 since it's not mentioned in the criteria as EGFR is but in all likelihood they are and just never bothered to update the protocol on clintrials. But IMHO this 1st-line data was looked at by the agency before SPPI got their blessing to run 2 new cohorts in their trial. I also went back to the 2nd Q transcript and TR specifically says that MDA will be focusing on the pan tumor study

MD Anderson will soon be initiating a pan-tumor cohort to their existing poziotinib trial.

we should be hearing news of that in the not too distant future. Go pozi! Go SPPI!